Brits issued urgent 'nightmare' warning issued to anyone that eats cheese
A study claims that fans of cheese should be warned about the potential side effects and impact.
A study of over 1,000 people found that those with lactose intolerance reported overall worse quality sleep and significantly more bad dreams
Can say with 100% certainty that cheese before bed does not give me nightmares. pic.twitter.com/Xxf1fuTYhI
— Bob (@WausauBob) July 2, 2025
They said dairy may cause 'gastrointestinal disturbance' that can disrupt sleep.
Study author Dr Tore Nielsen, from the University of Montreal, in Canada, said: 'Nightmares are worse for lactose-intolerant people who suffer severe gastrointestinal symptoms and whose sleep is disrupted.
'This makes sense because we know that other bodily sensations can affect dreaming. These findings imply that changing eating habits for people with food sensitivities could alleviate nightmares.
'They could also explain why people so often blame dairy for bad dreams. We're routinely asked whether food affects dreaming. Now we have some answers.'
Experts reckon digesting dairy can cause gut pain that plays havoc with the sleeping brain. Speaking previously, Dr Dennis Schmoltzi, CEO at Emma Sleep, said: 'Whether scientifically proven or just an old wives' tale, there's no doubt that Brits have identified a link between their cheese intake, and the strange visions that feature in their dreams.
Recommended reading:
Ryanair issues warning to passengers over 'free' hand luggage rule
Helen Skelton on mental health and importance of 'speaking to people in pubs'
Nationwide offering fresh £280 in free bonuses to thousands of customers
'Unfortunately for those who believe they have had a cheese-induced night-fright, 'tis the season to be cheesy – and vivid dreams may be part and parcel with Christmas celebrations.
'The admiration and love for cheese felt by Brits is clear to see – and with Christmas on the horizon, I have no doubt that households across the country are dusting off their cheese boards.
'It is interesting to note the number of cheese-lovers who feel snoozy after indulging in their favourite snack – a relationship which might account for a portion of the unscheduled festive naps taken this Christmas.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Hemostemix Closes $469,366 Private Placement
Calgary, Alberta--(Newsfile Corp. - July 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that the TSX Venture Exchange ("TSXV") conditionally approved the Company's previously disclosed non-brokered private placement (the "Offering") in the amount of CAD $469,366. The Offering consisted of the issuance of 3,911,385 Common Shares at a price of CAD $0.12. As per TSXV Policy 4.1, the investor is arm's length to the Company and is not a Related Party to the Company at the time of disclosure. The use of proceeds will be allocated to general working capital purposes, supporting the Company's continuing operational expenses and business development activities. The Company confirms that there is no material fact or material change about the Company that has not been generally disclosed. All securities issued in connection with the Offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. ABOUT HEMOSTEMIXHemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in ten peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 60% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@ / PH: 905-580-4170 Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the Closing of a non brokered private placement, in furtherance of sales in Florida of VesCell (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
2 hours ago
- Associated Press
WELL Health Announces Voting Results for Election of Directors
VANCOUVER, British Columbia--(BUSINESS WIRE)--Jul 4, 2025-- WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the ' Company ' or ' WELL '), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that at its annual general meeting held June 30, 2025 (the ' Meeting '), all of the nominees for election as directors of the Company referred to in its notice of meeting and information circular dated May 28, 2025 for the Meeting were elected. A total of 67,105,724 common shares representing 26.52% of the outstanding common shares of the Company were voted by proxy at the Meeting. Voting results for the election of directors at the Meeting were as follows: The results of other matters considered at the Meeting are reported in the Report of Voting Results as filed on SEDAR+ ( ) filed on July 4, 2025. WELL HEALTH TECHNOLOGIES CORP. Per: 'Hamed Shahbazi' Hamed Shahbazi Chief Executive Officer, Chairman and Director About WELL Health Technologies Corp. WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 210 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about the Company, please visit: View source version on CONTACT: For further information: Tyler Baba Investor Relations, Manager [email protected] 604-628-7266 KEYWORD: NORTH AMERICA CANADA INDUSTRY KEYWORD: HEALTH TECHNOLOGY HEALTH TECHNOLOGY PRACTICE MANAGEMENT SOFTWARE GENERAL HEALTH SOURCE: WELL Health Technologies Corp. Copyright Business Wire 2025. PUB: 07/04/2025 07:01 AM/DISC: 07/04/2025 07:01 AM
Yahoo
4 hours ago
- Yahoo
Happy Belly Food Group's Heal Wellness QSR Announces the Opening of Its Newest Location in Aurora, Ontario
Toronto, Ontario--(Newsfile Corp. - July 4, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands across Canada is pleased to announce the opening of its 26th Heal Wellness, located in Aurora, Ontario. Heal Wellness ("Heal") is a fresh smoothie bowls, acai bowls, and smoothies quick serve restaurant ("QSR"). The Grand opening will be located at 15570 Yonge Street, Unit 2, Aurora, Ontario, this Saturday July 5th, 2025. Happy Belly 1 To view an enhanced version of this graphic, please visit: "This opening represents our 26th location open and operating, with more in construction and scheduled to be open throughout 2025," said Sean Black, Chief Executive Officer of Happy Belly. We have seen tremendous growth with Heal and the rest of the Happy Belly's portfolio of emerging brands culminating in our accelerated store opening growth across both corporate and franchise locations. This ongoing rollout reflects our disciplined blend of organic growth and strategic acquisitions. "With each new restaurant opening our national footprint continues to expand. Heal's first-mover advantage in our chosen markets has enabled us to experience significant growth with more units now under construction in Alberta, Ontario and P.E.I. Supported by 195 units already secured under development agreements stretching coast to coast we have set the stage for continued, predictable expansion as Heal becomes Canada's first true national smoothie bowl brand." Happy Belly 2 To view an enhanced version of this graphic, please visit: "With 606 retail locations under contract-spanning projects in development, under construction, or already open-our franchise pipeline is robust. By carefully selecting the right partners and prime real estate, we will maintain momentum and achieve our disciplined growth objectives through 2026." We are just getting Heal WellnessHeal Wellness was founded with a passion and mission to provide quick, fresh wellness foods that support a busy and active lifestyle. We currently offer a diverse range of smoothie bowls and smoothies. We take pride in meticulously selecting every superfood ingredient on our menu to fuel the body, including acai smoothie bowls, smoothies, and super-seed grain bowls. Our smoothie bowls are crafted with real fruit and enriched with superfoods like acai, pitaya, goji berries, chia seeds, and franchising inquiries, please see or contact us at hello@ About Happy Belly Food GroupHappy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company") is a leader in acquiring and scaling emerging food brands across Canada. Happy Belly 3 To view an enhanced version of this graphic, please visit: Sean BlackChief Executive Officer Shawn MonizChief Operating Officer FOR FURTHER INFORMATION, PLEASE VISIT: www: or email hello@ you wish to contact us, please call: 1-877-589-8805 Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management. Cautionary Note Regarding Forward-Looking Statements All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws. Forward-Looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include the future performance of Happy Belly and her subsidiaries. Forward-Looking statements are based on the opinions and estimates at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. There are no assurances that the business plans for Happy Belly described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on To view the source version of this press release, please visit Sign in to access your portfolio
